← All trials
NCT04031872
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Jul 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 31
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Netherlands Cancer InstituteLead sponsor
- Eli LillyCollaborator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Universidad Autonoma de BarcelonaCollaborator
- University of TurinCollaborator
- University of AmsterdamOverall official - principal investigator
- Katholieke Universiteit LeuvenCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- University of Campania Luigi VanvitelliCollaborator
- University of ValenciaCollaborator
- AgendiaCollaborator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoCollaborator
- Catalan Institute of HealthCollaborator
- INCLIVAOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.